Posts Tagged ‘warfarin’

Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study

The actual consequence of suboptimal anticoagulation management in patients with nonvalvular atrial fibrillation (NVAF) is unclear in the real-life practice.

Esther W. Chan PhD, Wallis C.Y. Lau BSc, Chung Wah Siu MD, Gregory Y.H. Lip MD, Wai K. Leung MD, Shweta Anand BDS, Kenneth K.C. Man MPH and Ian C.K. Wong PhD
Heart Rhythm, 2016-08-01, Volume 13, Issue 8, Pages 1581-1588, Copyright © 2016 Heart Rhythm Society

Relationships between anticoagulation regimen, risk score and adverse outcomes in dialysis patients with atrial fibrillation

Atrial fibrillation (AF) is the commonest cardiac arrhythmia including in end-stage renal failure patients, and there is increasing evidence that anticoagulation leads to more harm than benefit in these patients on dialysis. We reviewed the characteristics, management and outcomes of end-stage renal failure patients in dialysis with AF with a focus on warfarin anticoagulation and risk scores.

T. Wang, J. Sathananthan, C. Hood, G. Gamble, M. Marshall, A. Kerr
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Warfarin vs Dabigatran for elective direct current cardioversion (DCCV)

In clinical practice, achieving 4 weeks of therapeutic anticoagulation with warfarin is challenging and hinders timely DCCV. Dabigatran is a safe and effective alternative. We evaluated the difference in time to DCCV and success rate between those on dabigatran compared to warfarin.

A. Kueh, D. Judson, K. Reed, R. Gabriel, J. Looi, D. Heaven, N. van Pelt
Counties Manukau District Health, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Interested in joining CSANZ?